Mumbai based global generics, specialty and OTC pharmaceutical maker selling in more than 80 countries
glenmarkpharma.comLegal name
Glenmark Pharmaceuticals Limited
Founded
1977
Headquarters
Glenmark House, B. D. Sawant Marg, Chakala, Andheri (E), Mumbai 400099, Maharashtra, IndiaIndustry
Pharmaceuticals and biotechnology (generics, specialty, OTC)
Chairman & Managing Director
Glenn Saldanha
CFO
Anurag Mantri, Executive Director & Global Chief Financial Officer
Employees
15,648 on LinkedIn, company size band 10,001+
Market Cap
INR 61,619 crore (Screener, moves with the share price)
Listed on
NSE: GLENMARK, BSE: 532296
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company founded in 1977 by Gracias Saldanha and headquartered in Mumbai. It listed in India in 1999 and trades as GLENMARK on the NSE and 532296 on the BSE. Glenn Saldanha, the founder's son, is Chairman and Managing Director, and Anurag Mantri is Executive Director and Global Chief Financial Officer.
The company sells generics, specialty and OTC medicines in more than 80 countries, with respiratory, dermatology and oncology as its core therapy areas. It ranks among the top 15 pharmaceutical companies in India and is one of the larger generic suppliers by prescriptions filled in the United States. Manufacturing runs across roughly 11 sites, including Nashik, Baddi, Nalagarh, Goa, Indore, Sikkim and Chhatrapati Sambhajinagar in India, plus plants in the United States, Argentina and the Czech Republic.
For FY26 Glenmark reported consolidated revenue of INR 169,825 million, up 27.5% year on year, with EBITDA of INR 45,724 million and profit after tax of INR 13,620 million. The year was shaped by a global licensing deal its innovation arm Ichnos Glenmark Innovation signed with AbbVie for the cancer candidate ISB 2001, carrying a USD 700 million upfront payment and up to USD 1.925 billion in total value. The company employs roughly 15,600 people per its LinkedIn profile.
Chairman & Managing Director
Executive Director & Global Chief Financial Officer
Executive Director, Corporate Services
President & Chief Human Resources Officer
Interview experience
7 out of 10, favourable
Interview difficulty
Medium, 5 out of 10
Interview process length
About a day or two for most candidates
Practise the questions candidates actually get asked and get instant feedback on your answers.
Q: Introduction
A: Keep it to about 60 seconds: your qualification, the plant or lab work you've done, and why pharma manufacturing interests you. Close by pointing at the role you're interviewing for.
Q: Why should we hire you
A: Pick two strengths that map to the job description and back each with a short example. Don't list adjectives, show evidence.
Q: Data integrity and it's classification
A: Data integrity means records stay complete, consistent and accurate through their whole life. The usual framing is ALCOA and ALCOA Plus, and interviewers also expect you to separate static from dynamic data.
Q: About Granulation
A: Granulation turns fine powder into larger, free flowing granules so blends stay uniform and compress well. Be ready to compare wet and dry granulation and say when you'd pick each.
Practise the questions candidates actually get asked and get instant feedback on your answers.
Reported average
₹9,71,669 per year
7 salaries reported Salaries submitted
Reported average
₹16,96,558 per year
6 salaries reported Salaries submitted
Reported average
₹10,41,402 per year
3 salaries reported Salaries submitted
Survey average
₹6,20,000 per year
about 5 survey responses Salaries submitted
Survey range
₹3,75,000 to ₹8,96,000 per year
about 5 survey responses Salaries submitted
Survey range
₹3,80,000 to ₹9,45,000 per year
about 5 survey responses Salaries submitted
Compare reported pay across roles and see which openings match your experience.
Mumbai Metropolitan Region • Full-time
Mumbai, Maharashtra • Full-time
Mumbai, Maharashtra • Full-time
Mumbai, Maharashtra • Full-time
Mumbai Metropolitan Region • Full-time
Mumbai Metropolitan Region • Full-time
Tailor your resume to each Glenmark posting in minutes.
July 21, 2026
US FDA expands RYALTRIS nasal spray to children aged 6 to under 12
Glenmark received U.S. FDA approval widening the label for its RYALTRIS nasal spray to children aged 6 to less than 12 years. It extends the reach of one of the company's lead respiratory brands.
#FDAapproval #Respiratory #Pharma
View postJuly 2, 2026
Glenmark advances multi-country Phase 3 trial of trastuzumab rezetecan
The company said it is moving ahead with a multi-country Phase 3 clinical trial of trastuzumab rezetecan in platinum resistant ovarian cancer. The programme adds to Glenmark's oncology pipeline work.
#Oncology #ClinicalTrials #RnD
View postJune 11, 2026
Winlevi (clascoterone) cream launched in key European markets
Glenmark launched its acne treatment Winlevi 10 mg/g cream across several major European markets. The launch builds out its dermatology specialty portfolio in Europe.
#Dermatology #ProductLaunch #Europe
View postMay 29, 2026
FY26 revenue up 27.5% to INR 169,825 million
Glenmark reported FY26 consolidated revenue of INR 169,825 million with EBITDA of INR 45,724 million and profit after tax of INR 13,620 million. Its India business grew at about 1.5 times the domestic market rate.
#Earnings #FY26 #Pharma
View postMarch 21, 2026
GLIPIQ semaglutide launched in India
Glenmark launched GLIPIQ, its semaglutide product, in India for its diabetes portfolio. The launch widens the company's presence in type 2 diabetes therapy at home.
#ProductLaunch #Diabetes #India
View postGlenmark Pharmaceuticals is an Indian multinational drug maker selling generics, specialty and OTC medicines in more than 80 countries. Respiratory, dermatology and oncology are its core therapy areas.
